ecancermedicalscience

Case Report

Dealing with pre-existing chronic neutropenia in cancer patients— considerations and consequences in the clinical praxis

29 Oct 2020
Anna-Birgitte Thinggaard, Gabor Liposits, Niels Fristrup

Chronic neutropenia is a rare but important challenge with substantial clinical implications for patients receiving antineoplastic treatment. Treatment-induced neutropenia is a well-known adverse event during chemotherapy and some targeted treatments. Guidelines for administering chemotherapy are rather strict to protect the patient from severe and life-threatening complications. Consequently, patients with chronic neutropenia may receive suboptimal antineoplastic treatment. Autoimmune neutropenia or chronic idiopathic neutropenia (CIN) may affect the antineoplastic treatment by causing delayed drug delivery, dose reductions and early discontinuation of treatment. CIN is characterised by the onset in late childhood or adulthood, affects mostly women, is clinically benign and has rare spontaneous remission. Here, we elucidate the challenges related to chronic neutropenia when administering chemotherapy through two clinical cases. Guidelines may need to be revised in order to optimise the treatment of patients with asymptomatic chronic neutropenia, thus personalising the medical decisions for each patient.

Related Articles

Chase Peng Yun Ng, Moira Hegyi, Grant Lewison, Tania Pastrana, Eve Namisango, James Cleary, Barbara Hasties, Eric Kabisa, Helena Musau, Kathryn Spangenberg, Paola Ruiz, Zipporah Ali, Mertixell Mallafre-Larrosa, Alfredo Polo, Julie Torode, Ajay Aggarwal, Richard Sullivan, Mevhibe Hocaoglu
Sergine Cindy M Zeufack, Jackton Omoto, Antony Owaya, Everlyn Adoyo, Mercy Rop, Cirillus Ogollah Osongo, Lisa Rahangdale, Craig R Cohen, Chemtai Mungo
Association of Medical and Pediatric Oncologists of Kerala (AMPOK)